Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 12.73 | — | 20.67 | 25.16 | 10.41 | 21.74 | 101.39 | 20.46 | 35.78 | 15.48 | 13.67 | 9.38 | 10.54 | 15.80 | — | — | 303.41 | — | — | — | 22.45 |
| — | — | -79.6% | +23.0% | -70.9% | +40.4% | +641.8% | +118.1% | +239.4% | -2.0% | — | — | -96.5% | — | — | — | +1251.6% | — | — | — | +38.0% | |
| P/S Ratio | 0.92 | 1.47 | 1.71 | 2.24 | 1.65 | 1.54 | 1.38 | 1.58 | 2.44 | 2.24 | 2.77 | 2.12 | 1.72 | 1.70 | 1.42 | 1.50 | 1.09 | 1.22 | 2.05 | 5.82 | 2.27 |
| — | -4.3% | +24.2% | +41.7% | -32.3% | -31.3% | -50.3% | -25.6% | +41.7% | +31.8% | +95.2% | +41.2% | +57.7% | +39.3% | -30.5% | -74.2% | -52.0% | -58.6% | -26.4% | +150.5% | -1.5% | |
| P/B Ratio | 2.90 | 3.77 | 4.24 | 6.09 | 5.02 | 4.98 | 4.18 | 5.02 | 6.62 | 6.00 | 7.24 | 6.50 | 5.26 | 4.59 | 4.58 | 4.00 | 2.81 | 3.05 | 3.50 | 3.14 | 2.85 |
| — | -24.3% | +1.4% | +21.3% | -24.2% | -17.1% | -42.2% | -22.8% | +26.1% | +30.9% | +58.1% | +62.6% | +87.1% | +50.4% | +31.0% | +27.3% | -1.6% | -20.9% | -39.1% | -17.6% | -32.5% | |
| P/FCF | 2.18 | 4.15 | 5.83 | 3.76 | 4.41 | 3.99 | 4.49 | 3.42 | — | 4.84 | 6.55 | 4.34 | 3.18 | 2.31 | 7.49 | 2.98 | 3.25 | 3.77 | — | 4.47 | 10.55 |
| — | +3.9% | +29.8% | +9.9% | — | -17.6% | -31.5% | -21.3% | — | +109.7% | -12.5% | +45.7% | -2.1% | -38.7% | — | -33.3% | -69.2% | -55.5% | — | -46.9% | +83.6% | |
| EV / EBITDA | 3.40 | 6.95 | 5.30 | 2.76 | 4.47 | 5.09 | 5.52 | 5.12 | 7.79 | 5.08 | 5.92 | 4.39 | 4.26 | 4.74 | 5.41 | 5.99 | 4.93 | 6.23 | 35.24 | — | 6.32 |
| — | +36.6% | -4.0% | -46.1% | -42.7% | +0.1% | -6.7% | +16.6% | +82.9% | +7.4% | +9.3% | -26.7% | -13.5% | -24.0% | -84.6% | — | -22.0% | -20.6% | +398.4% | — | +10.0% | |
| EV / EBIT | 7.50 | 79.48 | 13.47 | 4.72 | 8.23 | 12.45 | 18.07 | 12.14 | 17.57 | 9.44 | 9.31 | 6.46 | 7.06 | 8.82 | 87.86 | 25.71 | 14.06 | 27.77 | — | — | 14.02 |
| — | +538.3% | -25.5% | -61.1% | -53.2% | +31.9% | +94.0% | +87.8% | +148.7% | +7.0% | -89.4% | -74.9% | -49.8% | -68.2% | — | — | +0.3% | +72.7% | — | — | +30.8% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.3% | 55.2% | 60.6% | 62.5% | 61.7% | 57.7% | 54.8% | 54.0% | 60.8% | 62.5% | 63.1% | 63.2% | 58.7% | 54.5% | 53.5% | 38.4% | 46.3% | 42.4% | 57.9% | -4.9% | 58.5% |
| — | -4.3% | +10.7% | +15.7% | +1.5% | -7.8% | -13.2% | -14.5% | +3.4% | +14.8% | +18.0% | +64.5% | +26.8% | +28.5% | -7.7% | +888.5% | -20.8% | -30.0% | -8.6% | -108.4% | -3.9% | |
| Operating Margin | 24.0% | 1.9% | 16.5% | 28.8% | 30.4% | 18.7% | 12.2% | 20.9% | 21.9% | 32.7% | 34.1% | 41.2% | 32.9% | 26.3% | 17.0% | 9.1% | 16.1% | 9.0% | -12.0% | -124.7% | 17.9% |
| — | -90.1% | +35.4% | +37.6% | +38.9% | -42.9% | -64.3% | -49.2% | -33.6% | +24.3% | +100.7% | +354.2% | +104.3% | +192.3% | +242.3% | +107.3% | -10.2% | -54.5% | -149.5% | -734.3% | -27.6% | |
| Net Margin | 8.1% | -7.5% | 7.5% | 8.3% | 15.0% | 6.4% | 1.4% | 6.9% | 5.9% | 13.5% | 19.1% | 21.3% | 15.1% | 9.6% | -12.0% | -5.6% | 0.4% | -4.2% | -15.6% | -91.5% | 10.2% |
| — | -218.1% | +450.9% | +19.8% | +156.8% | -52.8% | -92.9% | -67.7% | -61.2% | +40.6% | +258.9% | +484.0% | +4094.9% | +328.4% | +22.9% | +93.9% | -96.5% | -104.8% | -187.4% | -1102.9% | -28.4% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 23.7% | -4.8% | 4.7% | 5.9% | 12.4% | 5.1% | 1.0% | 5.4% | 4.1% | 8.9% | 13.3% | 17.1% | 10.9% | 6.8% | -9.3% | -3.7% | 0.2% | -2.6% | -6.6% | -11.0% | 3.2% |
| — | -193.9% | +352.5% | +8.7% | +200.1% | -42.5% | -92.1% | -68.3% | -61.9% | +30.7% | +242.6% | +564.7% | +4595.1% | +359.2% | -42.0% | +66.7% | -92.7% | -107.7% | -174.5% | -384.3% | -53.6% | |
| ROA | 3.8% | -0.8% | 0.9% | 1.0% | 2.0% | 0.7% | 0.1% | 0.8% | 0.7% | 1.8% | 2.5% | 2.8% | 1.7% | 1.1% | -1.5% | -0.6% | 0.0% | -0.4% | -1.3% | -3.5% | 1.1% |
| — | -206.9% | +497.3% | +36.7% | +183.6% | -58.9% | -94.0% | -72.4% | -59.8% | +68.9% | +268.2% | +554.0% | +4513.9% | +357.1% | -8.2% | +82.6% | -96.6% | -103.9% | -155.5% | -423.1% | -36.8% | |
| ROIC | 14.0% | 0.3% | 2.6% | 4.4% | 4.8% | 2.7% | 1.6% | 2.7% | 3.1% | 5.8% | 5.9% | 7.3% | 5.1% | 3.8% | 2.6% | 1.2% | 1.9% | 1.0% | -1.3% | -8.5% | 3.2% |
| — | -89.3% | +60.0% | +59.6% | +53.9% | -52.9% | -72.5% | -62.4% | -39.0% | +51.6% | +131.7% | +530.5% | +171.1% | +289.9% | +294.1% | +113.6% | -41.1% | -75.5% | -123.2% | -312.0% | -36.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.12 | 2.75 | 2.59 | 3.12 | 3.41 | 3.57 | 3.60 | 3.75 | 3.73 | 2.58 | 2.84 | 3.45 | 4.02 | 3.80 | 4.49 | 3.64 | 3.71 | 3.82 | 3.97 | 1.28 | 1.08 |
| — | -23.0% | -28.2% | -17.0% | -8.7% | +38.2% | +27.0% | +8.8% | -7.1% | -32.0% | -36.8% | -5.2% | +8.2% | -0.6% | +13.1% | +185.5% | +244.4% | +242.2% | +129.1% | -11.0% | -32.7% | |
| Debt / EBITDA | 2.28 | 12.53 | 9.19 | 4.11 | 7.79 | 9.04 | 10.79 | 9.08 | 11.42 | 6.75 | 7.42 | 6.94 | 8.75 | 10.32 | 12.84 | 12.93 | 12.53 | 15.24 | 80.81 | — | 8.62 |
| — | +38.6% | -14.8% | -54.8% | -31.7% | +34.0% | +45.4% | +30.8% | +30.5% | -34.6% | -42.2% | -46.3% | -30.2% | -32.3% | -84.1% | — | +45.4% | +81.4% | +955.3% | — | +14.1% | |
| Current Ratio | 1.57 | 1.03 | 1.71 | 1.57 | 1.36 | 1.18 | 1.08 | 0.95 | 0.97 | 1.11 | 1.21 | 1.17 | 1.16 | 1.24 | 1.21 | 0.97 | 0.98 | 0.99 | 0.97 | 1.13 | 1.35 |
| — | -12.8% | +58.2% | +66.0% | +40.3% | +7.0% | -10.3% | -19.4% | -16.4% | -10.5% | +0.0% | +21.2% | +18.2% | +25.1% | +24.0% | -14.2% | -27.6% | -29.7% | -24.4% | -2.7% | +24.9% | |
| Quick Ratio | 1.48 | 0.84 | 1.62 | 1.48 | 1.27 | 1.10 | 1.01 | 0.88 | 0.88 | 1.04 | 1.14 | 1.10 | 1.08 | 1.18 | 1.13 | 0.86 | 0.82 | 0.80 | 0.76 | 1.07 | 1.29 |
| — | -23.7% | +60.4% | +68.6% | +43.9% | +5.3% | -11.5% | -20.5% | -18.4% | -11.1% | +0.9% | +28.1% | +31.8% | +46.9% | +48.6% | -19.3% | -36.1% | -39.3% | -37.8% | -2.6% | +27.3% | |
| Interest Coverage | 2.13 | 0.31 | 2.18 | 1.28 | 3.00 | 1.83 | 1.15 | 1.76 | 1.85 | 2.87 | 3.11 | 3.42 | 2.39 | 1.81 | 0.18 | 0.62 | 1.08 | 0.63 | -1.72 | -7.17 | 2.77 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying COLL stock.
Collegium Pharmaceutical, Inc.'s current P/E is 12.7x. The average P/E over the last 3 quarters is 18.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Collegium Pharmaceutical, Inc.'s current operating margin is 24.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Collegium Pharmaceutical, Inc.'s business trajectory between earnings reports.